Evidence-based clinical review C. difficile in 2026: Are We Finally Preventing Recurrence More Effectively? Fidaxomicin, microbiota restoration, and risk-stratified care have changed the recurrence conversation, but access and evidence gaps still matter. Estimated reading time: 16 minutes
Tag: Clostridioides difficile
